|
|
11621 Research Circle
Alachua, FL 32615 USA
phone:386.418.8888
fax:386.418.0342
|
|
| Symbol |
RTIX |
| Exchange |
Nasdaq |
| Founded |
1998 |
| Employees |
450 |
|
|
| www.rtix.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Processes and sterilizes human tissue into allograft implants. |
|
| Management |
| Brian K. Hutchison, Chairman and CEO; Thomas F. Rose, Executive Vice President and CFO; Roger W. Rose, Executive Vice President, RTI Biologics and President, RTI Donor Services; Caroline A. Hartill, Chief Scientific Officer and Vice President, Quality Assurance & Regulatory Affairs; Karl H. Koschatzky, Ph.D., President, International |
| |
|
|
|
|
|
|
| Recent Results |
| For the three months ended March 31st 2006 revenues increased 23% to $18.4M. Net loss increased 4% to $1.3M. Revenues reflect contributions from Spinal Constructs, Bone Graft Substitutes, Sports Medicine and General Orthopedic segments. The higher loss reflects increase in costs of processing and distribution expense, higher marketing, general and administrative expense. |
| |
|
|
|
|
| Keywords |
| biocompatibility, biologic, xenograft, orthopedic, allograft-associated |
|
|
|
| Description |
|
RTI Biologics fromerly known as Regeneration Technologies, Inc. (RTI) processes allograft and xenograft tissue into shaped implants for use in orthopaedic, cardiovascular, oral maxillofacial and urinary surgeries. |
|
| Products / Services |
Spinal Allografts, Sports Medicine, Cardiovascular, General Orthopedic Allografts and other allografts including Oral/dental and Urological
The source of all allografts is tissue that has been donated by people upon their death, with the consent of their family or loved ones.
RTI's Sterling Biological Matrix is bovine xenograft bone sterlized through the BioCleanse process. It provides an option for procedures previously limited by tissue availability and material constraints.
|
|
| Technology / Differentiation |
| RTI holds the patents on BioCleanse, a tissue sterilization process that eliminates viruses, bacteria, fungi and spores from tissue without impacting the structural or biomechanical integrity of the allograft. The company has distributed nearly 600,000 implants sterilized with the BioCleanse process with zero incidence of infection. |
|
| Market / Customers |
RTI sells its products in a range of markets, including spinal, sports medicine, cardiovascular and other general orthopedic applications.
|
|
| Strategy |
In 2005 the Company hired a direct sales team to sell their products.
|
|
|
|
| |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
